Clinical Trial
Accepted on 05 Mar 2026
Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers
in Cancer Immunity and Immunotherapy
Clinical Trial
Accepted on 05 Mar 2026
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 05 Mar 2026
in Land, Livelihoods and Food Security
Original Research
Accepted on 05 Mar 2026
in Bird Conservation and Management
Clinical Trial
Accepted on 05 Mar 2026
in Addictive Disorders
Original Research
Accepted on 05 Mar 2026
Review
Accepted on 05 Mar 2026
in Plant Biotechnology
Original Research
Accepted on 05 Mar 2026
in Dermatology
Original Research
Accepted on 05 Mar 2026
in Crop Biology and Sustainability
Original Research
Accepted on 05 Mar 2026
in Sustainable and Intelligent Phytoprotection
Original Research
Accepted on 05 Mar 2026
in Microorganisms in Vertebrate Digestive Systems
Original Research
Accepted on 05 Mar 2026
in Immunological Tolerance and Regulation
Editorial
Accepted on 05 Mar 2026
in Petrology
Editorial
Accepted on 05 Mar 2026
in Fungal Pathogenesis
Systematic Review
Accepted on 05 Mar 2026
in Primary Immunodeficiencies
Correction
Accepted on 05 Mar 2026
in Cognition
Original Research
Accepted on 05 Mar 2026
in Experimental Pharmacology and Drug Discovery